


**Table S1** Immunotherapy or chemo-immunotherapy regimens used in this study

Immunotherapy regimens	No.
ICI (s) alone	
Pembrolizumab	3
Nivolumab	3
Nivolumab + ipilimumab	1
Sintilimab	1
Single ICI plus platinum doublets	
Pembrolizumab + paclitaxel plus platinum	5
Pembrolizumab + pemetrexed plus platinum	12
Pembrolizumab + gemcitabine plus platinum	2
Nivolumab + docetaxel plus platinum	1
Nivolumab + paclitaxel plus platinum	3
Nivolumab + pemetrexed plus platinum	2
Nivolumab + gemcitabine plus platinum	4
Sintilimab + paclitaxel + carboplatin	1
Sintilimab + docetaxel plus platinum	1

ICI, immune checkpoint inhibitors.



**Figure S1** Immunohistochemistry staining of biopsy samples before neoadjuvant therapy. Scale bar, 400  $\mu$ M. LUSC, lung squamous cell carcinoma.